BioHarvest Sciences Reports Mixed Q1: Revenue Up 8%, Losses Widen Amid CDMO Progress
summarizeSummary
BioHarvest Sciences reported mixed first-quarter 2026 financial results, with total revenues increasing 8% year-over-year to $8.5 million, but operating loss widened to $1.8 million and net loss grew to $2.6 million. The company also provided a business update, highlighting progress in its CDMO division, including the advancement of two major Botanical Synthesis programs into Stage 2 development with combined agreements valued over $2 million. This update reiterates information previously announced on May 12th and 13th regarding a $1.2 million Stage 2 contract for a rare fragrance and the successful completion of Stage 1 for its saffron composition. While operational progress in the CDMO segment is positive, the widening losses despite revenue growth present a mixed financial picture for investors. Traders will be watching for future reports to see if the company can translate its CDMO advancements into improved profitability and reduced losses.
At the time of this announcement, BHST was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.8M. The 52-week trading range was $3.57 to $12.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.